302P Treatment patterns in resectable early-stage NSCLC in Taiwan: Subgroup analysis of a global real-world study

Abstract

Complete surgical resection is the recommended treatment for early-stage NSCLC, followed by adjuvant chemotherapy for patients (pts) with resectable stage II–IIIA and select stage IB disease; however, many pts will experience disease recurrence within five yrs post-surgery. Osimertinib, an EGFR-TKI, is approved as adjuvant therapy for pts with resected stage IB–IIIA EGFR-mutated (EGFRm) NSCLC based on results from the Phase III ADAURA trial. We conducted a global, non-interventional study in pts with resectable NSCLC and EGFR test results available to better understand RW EGFRm frequency, treatment practices and recurrence.